TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16752583

Group type: EXPERIMENTAL
Intervention: BD(DXA)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: BD(MD)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: BD(DXA) and BD(MD)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Clinical DXA densitometers
Number of subjects: 17
Study: 12634436

Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCTs)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Long-chain triglycerides (LCTs)
Number of subjects: 24
Study: 10692004

Group type: EXPERIMENTAL
Intervention: Encapsulated fish oil (FO) providing 2.1 g eicosapentaenoic acid (EPA) plus 1.1 g docosahexaenoic acid (DHA) per day for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo oil (3:1 mix of coconut and soybean oils)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Olive oil (OO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Safflower oil (SO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Evening primrose oil (EPO)
Number of subjects: 0
Study: 9109791

Group type: COMPARATOR
Intervention: Standard fractionation radiotherapy
Number of subjects: 336

Group type: COMPARATOR
Intervention: Hyperfractionation radiotherapy
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Surgery after radiotherapy
Number of subjects: 336
Study: 8259343

Group type: EXPERIMENTAL
Intervention: buserelin+nilutamide (Anandron)
Number of subjects: 36

Group type: COMPARATOR
Intervention: buserelin+placebo
Number of subjects: 36
Study: 3896665

Group type: EXPERIMENTAL
Intervention: 200 mg dimetophrine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30466512

Group type: EXPERIMENTAL
Intervention: NT-proBNP-guided therapy
Number of subjects: 894

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 894
Study: 26899862

Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone (8 mg mixed with ropivacaine)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (8 mg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Dexamethasone (both routes)
Number of subjects: 120
Study: 25514302

Group type: EXPERIMENTAL
Intervention: Entecavir (0.5 mg daily)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Lamivudine (100 mg daily)
Number of subjects: 121
Study: 22537778

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (α-Vit E)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ascorbic acid (Vit C)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol acetate (α-Vit E-acetate)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Lipoic acid
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ascorbyl 6-palmitate
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 2-glucoside
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Glutathione (GSH)
Number of subjects: 7
Study: 20575613

Group type: EXPERIMENTAL
Intervention: e-contact via e-mail and SMS communication
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: e-contact via SMS
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: e-contact via e-mail
Number of subjects: 49
Study: 17638396

Group type: EXPERIMENTAL
Intervention: Nicotine patch (16.6mg nicotine/patch) in former smokers (group 2)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (non-smokers, group 1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (current smokers, group 3)
Number of subjects: 75
Study: 16054963

Group type: EXPERIMENTAL
Intervention: Contraceptive patch (n = 846)
Number of subjects: 1489

Group type: COMPARATOR
Intervention: Oral contraception (OC) (n = 643)
Number of subjects: 1489

Group type: EXPERIMENTAL
Intervention: Contraceptive patch
Number of subjects: 1489
Study: 12134249

Group type: EXPERIMENTAL
Intervention: Intranasal interferon (IFN)‐alpha2b (6 x 10(6) U every 12 h x 3) plus oral chlorpheniramine (12 mg extended release) and ibuprofen (400 mg) every 12 h for 4.5 days (n=59 subjects)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intranasal placebo plus oral chlorpheniramine and ibuprofen (n=61 subjects)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Intranasal and oral placebos (n=30 subjects)
Number of subjects: 150
Study: 11756911

Group type: EXPERIMENTAL
Intervention: Combination of music and patient-controlled sedation with a mixture of propofol and alfentanil
Number of subjects: 165

Group type: COMPARATOR
Intervention: Patient-controlled sedation alone
Number of subjects: 165

Group type: COMPARATOR
Intervention: Music alone with diazemuls and meperidine administered intravenously if requested
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Combination of music and patient-controlled sedation
Number of subjects: 165
Study: 9744709

Group type: EXPERIMENTAL
Intervention: Interregional nurse-coordinated cardiovascular health care model
Number of subjects: 154

Group type: COMPARATOR
Intervention: Comparison group (standard care)
Number of subjects: 154
Study: 7838930

Group type: EXPERIMENTAL
Intervention: Low nicotine cigarette condition
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Medium nicotine cigarette condition
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High nicotine cigarette condition
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham smoking condition
Number of subjects: 29

Group type: COMPARATOR
Intervention: Non-smoking condition
Number of subjects: 29
Study: 2904237

Group type: EXPERIMENTAL
Intervention: Daily treatment with streptomycin, isoniazid, rifampin, and pyrazinamide for 2 months (2SHRZ) followed by 3‐times‐weekly isoniazid and rifampin (H3 R3)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Daily treatment with isoniazid, rifampin, and pyrazinamide for 1 month (1SHRZ) followed by 3‐times‐weekly isoniazid and rifampin (H3 R3)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Daily treatment with isoniazid, rifampin, and pyrazinamide for 2 months without streptomycin (2HRZ) followed by 3‐times‐weekly isoniazid and rifampin (H3 R3)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Patients with drug‐susceptible strains pretreatment
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Patients with strains resistant to isoniazid, streptomycin, or both drugs pretreatment
Number of subjects: 297
Study: 29189607

Group type: EXPERIMENTAL
Intervention: K12 (2.5 × 10(9) cfu per lozenge)
Number of subjects: 1314

Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 1314

Group type: EXPERIMENTAL
Intervention: K12
Number of subjects: 1314
Study: 27543900

Group type: EXPERIMENTAL
Intervention: Intracoronary delivery of allogeneic cardiosphere-derived cells (CAP-1002)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 26852498

Group type: EXPERIMENTAL
Intervention: Combination of intermittent pneumatic compression, kinesio-taping, and underwater massage shower
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intermittent pneumatic compression and underwater massage shower
Number of subjects: 30
Study: 23287525

Group type: EXPERIMENTAL
Intervention: 0.3 ms ultra-brief pulse right unilateral ECT
Number of subjects: 35

Group type: COMPARATOR
Intervention: 1 ms-brief pulse right unilateral ECT
Number of subjects: 35
Study: 21636200

Group type: EXPERIMENTAL
Intervention: Upper threshold normocapnia (corrected pCO₂ 6.0 kPa)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lower threshold normocapnia (non-corrected pCO₂ 4.2 kPa)
Number of subjects: 8
Study: 18055869

Group type: EXPERIMENTAL
Intervention: Fludarabine and cyclophosphamide (FC)
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Fludarabine (single-agent)
Number of subjects: 777

Group type: COMPARATOR
Intervention: Chlorambucil or Fludarabine
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: Fludarabine monotherapy
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: DAT status at initiation of therapy
Number of subjects: 777
Study: 16476713

Group type: EXPERIMENTAL
Intervention: Celecoxib (CBX) 200 mg/24 h
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Aceclofenac (ACF) 100 mg/12 h
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (patients with OA who did not want to be treated with NSAIDs)
Number of subjects: 30
Study: 12730296

Group type: COMPARATOR
Intervention: Nonfat placebo beverage (NF)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nonfat beverage with added phytosterols (NFPS)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Low-fat beverage with added phytosterols (LFPS)
Number of subjects: 15
Study: 11099750

Group type: EXPERIMENTAL
Intervention: INN 00835 (0.2 mg/kg subcutaneously for 5 consecutive days)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: INN 00835
Number of subjects: 52
Study: 9368550

Group type: EXPERIMENTAL
Intervention: t-PA treatment
Number of subjects: 312
Study: 1311535

Group type: EXPERIMENTAL
Intervention: Infusion of mivacurium at a rate of 6 +/- 2 micrograms.kg‐1.min‐1 after an initial bolus of 2 x ED95.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Repeated injection of mivacurium at 0.6 x ED95 whenever twitch tension recovered to 25% of control.
Number of subjects: 65

Group type: COMPARATOR
Intervention: Neostigmine (7 micrograms/kg) administered at 25% twitch recovery in both groups.
Number of subjects: 65
Study: 30777901

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Midazolam (MDZ)
Number of subjects: 120
Study: 28285208

Group type: EXPERIMENTAL
Intervention: Varenicline and cognitive-behavioral therapy for smoking cessation
Number of subjects: 153
Study: 26211378

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 60
Study: 23541425

Group type: EXPERIMENTAL
Intervention: AZD1386
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 103

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 103
Study: 21129711

Group type: EXPERIMENTAL
Intervention: Right radial approach
Number of subjects: 193

Group type: COMPARATOR
Intervention: Left radial approach
Number of subjects: 193
Study: 19387697

Group type: EXPERIMENTAL
Intervention: Wallis interspinous implant (group W)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 45
Study: 16452735

Group type: EXPERIMENTAL
Intervention: Enoxaparin (30 mg, administered subcutaneously twice a day) starting 24-48 hours after blunt trauma
Number of subjects: 200

Group type: COMPARATOR
Intervention: Pulsatile foot pumps at admission combined with delayed enoxaparin
Number of subjects: 200
Study: 14747633

Group type: EXPERIMENTAL
Intervention: Fluoxetine, Paroxetine, or Sertraline (SSRI antidepressants)
Number of subjects: 573
Study: 11734484

Group type: EXPERIMENTAL
Intervention: Four-strand gracilis and semitendinosus tendon autograft (hamstring tendon group)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Patellar tendon-bone autograft (patellar tendon group)
Number of subjects: 72
Study: 9159623

Group type: EXPERIMENTAL
Intervention: Aortic homograft (group A)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pulmonary autograft (group B)
Number of subjects: 70
Study: 7659908

Group type: EXPERIMENTAL
Intervention: Dipyridamole Tc99m sestaMIBI SPECT
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Amrinone-echocardiography
Number of subjects: 37
Study: 2441458

Group type: EXPERIMENTAL
Intervention: Elmiron 200 mg X 2 daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29580885

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention consisting of educational lectures, posters, and pocket cards for thromboprophylaxis guidelines.
Number of subjects: 2962

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention in post-acute care wards.
Number of subjects: 2962

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention in long-term care wards.
Number of subjects: 2962

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 2962
Study: 26964857

Group type: EXPERIMENTAL
Intervention: Traditional complete denture group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Duplicate complete denture group
Number of subjects: 20
Study: 26591117

Group type: EXPERIMENTAL
Intervention: Research group (celebration of Rare Disease Day)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control group (23 February 2013)
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Research group
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 242
Study: 22357109

Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab (0.25 mg/kg bodyweight bolus followed by 12 h intravenous infusion at 0.125 μg/kg per min)
Number of subjects: 2065

Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab
Number of subjects: 2065

Group type: COMPARATOR
Intervention: Intravenous abciximab
Number of subjects: 2065
Study: 21115882

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg orally twice daily for 9 months
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 240
Study: 18787429

Group type: EXPERIMENTAL
Intervention: Silicone hydrogel lenses
Number of subjects: 55

Group type: COMPARATOR
Intervention: Habitual lenses
Number of subjects: 55
Study: 15893193

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFAs) 2 g/day
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study: 12948257

Group type: EXPERIMENTAL
Intervention: Polymethylmethacrylate (PMMA) alone
Number of subjects: 13

Group type: COMPARATOR
Intervention: Polymethylmethacrylate (PMMA) with Steinmann pin reinforcement
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal distal femurs
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Defective femurs
Number of subjects: 13
Study: 10390097

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 12
Study: 8661572

Group type: EXPERIMENTAL
Intervention: IV butylscopolamine (20 mg)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Oral dicyclomine (20 mg)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: IV glucagon (1 mg)
Number of subjects: 148

Group type: COMPARATOR
Intervention: No-drug control group
Number of subjects: 148
Study: 2004722

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timolol and Epinephrine mixture
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6858171

Group type: EXPERIMENTAL
Intervention: Prothromblex500 (factor II, IX and X)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Prothromblex Total500 (factor II, VII, IX and X)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Both concentrates
Number of subjects: 246
Study: 31711065

Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both groups (rTMS and sham)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 56
Study: 30745582

Group type: EXPERIMENTAL
Intervention: NK105 (65 mg/m2)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Paclitaxel (PTX) (80 mg/m2)
Number of subjects: 436
Study: 28407009

Group type: EXPERIMENTAL
Intervention: Refractive error treatment coverage in Indigenous Australians
Number of subjects: 4836

Group type: COMPARATOR
Intervention: Refractive error treatment coverage in non-Indigenous Australians
Number of subjects: 4836

Group type: EXPERIMENTAL
Intervention: Risk factors for low coverage in Indigenous Australians
Number of subjects: 4836

Group type: EXPERIMENTAL
Intervention: Protective factor for treatment of refractive error in Indigenous Australians
Number of subjects: 4836

Group type: EXPERIMENTAL
Intervention: Coverage for Indigenous Australians who had not undergone an eye examination within the past five years
Number of subjects: 4836

Group type: EXPERIMENTAL
Intervention: Coverage for Indigenous Australians who had never been examined
Number of subjects: 4836
Study: 26503218

Group type: EXPERIMENTAL
Intervention: Process-oriented training for health professionals (midwives and child health nurses)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group (no process-oriented training)
Number of subjects: 206
Study: 23499621

Group type: EXPERIMENTAL
Intervention: Electrogram-based AVO (SmartDelay)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Nominal atrioventricular delay (120 ms)
Number of subjects: 280
Study: 21852546

Group type: EXPERIMENTAL
Intervention: H10407 at doses of 10(7) CFU with bicarbonate
Number of subjects: 35

Group type: COMPARATOR
Intervention: Rechallenged volunteers (10 subjects)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: After the second challenge
Number of subjects: 35
Study: 19651565

Group type: EXPERIMENTAL
Intervention: Erythropoietin (300 U/kg or 500 U/kg) administered every other day for 2 weeks
Number of subjects: 167

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Erythropoietin (300 U/kg or 500 U/kg)
Number of subjects: 167
Study: 17335320

Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination
Number of subjects: 605

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 605

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 605
Study: 12413642

Group type: EXPERIMENTAL
Intervention: Clozapine treatment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Propranolol and Atenolol (beta-adrenergic antagonists)
Number of subjects: 50
Study: 10705175

Group type: EXPERIMENTAL
Intervention: Sennosides (Sen)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Non-sennosides (NSen)
Number of subjects: 32
Study: 9366462

Group type: EXPERIMENTAL
Intervention: Intramuscular rocuronium (1,000 microg/kg for infants and 1,800 microg/kg for children)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Intravenous rocuronium (not specified in detail)
Number of subjects: 29
Study: 8456595

Group type: EXPERIMENTAL
Intervention: Oxiracetam (1600 mg/day)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 3523298

Group type: EXPERIMENTAL
Intervention: Pirenzepine (10 mg e.v./8 hours, starting the day before surgery to 10th day after it)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Void period (without specific therapy)
Number of subjects: 40
Study: 29969209

Group type: EXPERIMENTAL
Intervention: GnRH antagonist pretreatment for three days
Number of subjects: 88

Group type: COMPARATOR
Intervention: Conventional antagonist protocols
Number of subjects: 88
Study: 26445354

Group type: EXPERIMENTAL
Intervention: Fetoscopic training
Number of subjects: 46

Group type: COMPARATOR
Intervention: Laparoscopic training
Number of subjects: 46
Study: 25495459

Group type: EXPERIMENTAL
Intervention: DVD Group
Number of subjects: 1108

Group type: COMPARATOR
Intervention: Standard Materials Group
Number of subjects: 1108
Study: 22334531

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo CPAP
Number of subjects: 28
Study: 20056900

Group type: EXPERIMENTAL
Intervention: AMG 317 75 mg
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: AMG 317 150 mg
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: AMG 317 300 mg
Number of subjects: 294

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 294
Study: 19343871

Group type: EXPERIMENTAL
Intervention: OXY‐TDS administration
Number of subjects: 0
Study: 15721109

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (sirolimus and paclitaxel)
Number of subjects: 5066
Study: 12743626

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amlodipine + HRT
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study: 10793931

Group type: EXPERIMENTAL
Intervention: Acellular pertussis vaccine
Number of subjects: 386

Group type: COMPARATOR
Intervention: Whole cell pertussis vaccine
Number of subjects: 386
Study: 8658029

Group type: EXPERIMENTAL
Intervention: Transient evoked otoacoustic emissions (TEOAEs)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Pure-tone audiometry
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: TEOAEs
Number of subjects: 95
Study: 1888632

Group type: EXPERIMENTAL
Intervention: Flosequinan (oral, administered for 14 days)
Number of subjects: 21
Study: 6126752

Group type: EXPERIMENTAL
Intervention: Preoperative external biliary drainage
Number of subjects: 57

Group type: COMPARATOR
Intervention: No preoperative external biliary drainage
Number of subjects: 57
Study: 30361793

Group type: EXPERIMENTAL
Intervention: PBM‐LLLT with 5% potassium nitrate (KNO3)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PBM‐LLLT without potassium nitrate (KNO3)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 5% potassium nitrate (KNO3) without PBM‐LLLT
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo gel application with mock PBM‐LLLT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PBM‐LLLT and KNO3 combined
Number of subjects: 50
Study: 30282144

Group type: EXPERIMENTAL
Intervention: 2% lidocaine 3 ml (Group A)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2% lidocaine 2 ml + physiological saline 1 ml (Group B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2% lidocaine 1 ml + physiological saline 2 ml (Group C)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Physiological saline 3 ml (Group D)
Number of subjects: 80
Study: 27553397

Group type: EXPERIMENTAL
Intervention: Intervention group (education and support groups, involvement in quality assessment activities)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (no intervention details provided)
Number of subjects: 185
Study: 25023641

Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (OPCABG)
Number of subjects: 106

Group type: COMPARATOR
Intervention: On-pump coronary artery bypass grafting (ONCABG)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both groups (OPCABG and ONCABG)
Number of subjects: 106